Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive phase 2 study of iptacopan added to standard therapy for active lupus nephritis
MOH_2022-08-10_011968Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Iptacopan in lupus nephritis (LN) and systemic lupus erythematosus (SLE) (5 arms), sponsored by Novartis. Started Aug 2022; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on MOH_2022-08-10_011968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-08-10_011968.